APA

Clavio M., Vignolo L., Albarello A., Varaldo R., Pierri I., Catania G., Balocco M., Michelis G., Miglino M., Manna A., Balleari E., Carella A. M., Sessarego M., Van Lint M. T., Bacigalupo A. & Gobbi M. (20070917). Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients. : British journal of haematology.

Chicago

Clavio Marino, Vignolo Luana, Albarello Alessandra, Varaldo Riccardo, Pierri Ivana, Catania Gioacchino, Balocco Manuela, Michelis Gianluca, Miglino Maurizio, Manna Annunziata, Balleari Enrico, Carella A Michele, Sessarego Mario, Van Lint Maria Teresa, Bacigalupo Andrea and Gobbi Marco. 20070917. Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients. : British journal of haematology.

Harvard

Clavio M., Vignolo L., Albarello A., Varaldo R., Pierri I., Catania G., Balocco M., Michelis G., Miglino M., Manna A., Balleari E., Carella A. M., Sessarego M., Van Lint M. T., Bacigalupo A. and Gobbi M. (20070917). Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients. : British journal of haematology.

MLA

Clavio Marino, Vignolo Luana, Albarello Alessandra, Varaldo Riccardo, Pierri Ivana, Catania Gioacchino, Balocco Manuela, Michelis Gianluca, Miglino Maurizio, Manna Annunziata, Balleari Enrico, Carella A Michele, Sessarego Mario, Van Lint Maria Teresa, Bacigalupo Andrea and Gobbi Marco. Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients. : British journal of haematology. 20070917.